Page last updated: 2024-12-05

12-crown-4

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

12-Crown-4, also known as 1,4,7,10-tetraoxacyclododecane, is a macrocyclic polyether consisting of a 12-membered ring containing four oxygen atoms. Its synthesis involves a multi-step process that often utilizes Williamson ether synthesis. 12-crown-4 is known for its complexation properties, forming stable complexes with alkali and alkaline earth metal cations. Its selectivity towards lithium cations is particularly noteworthy. 12-crown-4 is studied extensively in fields like chemistry, biology, and material science due to its potential applications in various areas, such as ion-selective electrodes, metal ion transport, and as a catalyst in organic reactions. The complexation behavior of 12-crown-4 with metal cations is a subject of active research, particularly its role in influencing reaction kinetics and selectivity.'

12-crown-4: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

12-crown-4 : A crown ether that is cyclododecane in which the carbon atoms at positions 1, 4, 7 and 10 have been replaced by oxygen atoms. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9269
CHEMBL ID4566196
CHEBI ID32399
SCHEMBL ID236725
MeSH IDM0556366

Synonyms (37)

Synonym
LS-13523
ethylene oxide cyclic tetramer
1,4,7,10-tetraoxacyclododecane
12-crown-4
12-crown-4 ether
CHEBI:32399
294-93-9
eoct
12-crown-4, cyclic tetramer of ethylene oxide which is specific for the lithium cation., 98%
brn 1363064
ccris 157
einecs 206-036-5
C-8590
12-crown 4-ether
inchi=1/c8h16o4/c1-2-10-5-6-12-8-7-11-4-3-9-1/h1-8h2
xqqzrzqvbfhbhl-uhfffaoysa-
3,6,9,12-tetraoxacyclododecan
A819938
5-19-11-00334 (beilstein handbook reference)
unii-k6069p2c2a
k6069p2c2a ,
FT-0607231
AKOS015907759
12-crown-4-ether
SCHEMBL236725
1,4,7,10-tetraoxacyclo-dodecane
DTXSID6059780
mfcd00005103
Q4261972
D89315
1,4,7,10tetraoxa-cyclododecane
12 c 4
12crown4
12-c-4
12c4
12 crown 4
CHEMBL4566196
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
crown etherCrown compounds containing only oxygen as coordinating atom.
saturated organic heteromonocyclic parent
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1614591Inhibition of ANS binding to TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as increase in BC50 for ANS binding to TTR at 100 mM in presence of 150 mM Na+ by fluorescence-based assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID1614579Inhibition of TTR V30M mutant (unknown origin)-mediated amyloid fibril formation expressed in Escherichia coli assessed as amyloid fibril percentage at 6 mM after 4 days by thioflavin-T-fluorescence based assay (Rvb = 100%)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID1614593Inhibition of ANS binding to TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as increase in BC50 for ANS binding to TTR at 100 mM in presence of 150 mM K+ by fluorescence-based assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID1614587Stabilization of TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as formation of TTR tetramer band formation at 40 to 100 mM after 4 mins by SDS-PAGE analysis based glutaraldehyde cross-linking assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID1614580Inhibition of TTR V30M mutant (unknown origin)-mediated amyloid fibril formation expressed in Escherichia coli assessed as amyloid fibril percentage at 20 mM after 4 days by thioflavin-T-fluorescence based assay (Rvb = 100%)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's13 (81.25)24.3611
2020's3 (18.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.51 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index55.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]